Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02365233 · ClinicalTrials.gov registry record · Phase 4
Fatty Liver Study in Patients With Type II Diabetes
A Phase 4 study, sponsored by The University of Texas Medical Branch, Galveston.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT02365233 is a Phase 4 study that was terminated before completion, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 5 participants.
The verdict
NCT02365233, a Phase 4 study, was terminated before completion, sponsored by The University of Texas Medical Branch, Galveston.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
The primary objective of this trial is to measure changes in hepatic lipid content using three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
Interventions
- DRUG Pioglitazone
- DRUG DPP4 inhibitor
- DRUG Lantus insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2013-05-01 |
| Est. Completion | 2016-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02365233
The ClinicalTrials.gov registry entry for NCT02365233 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pioglitazone is the first listed.
NCT02365233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02365233 about?
NCT02365233 is a clinical study titled "Fatty Liver Study in Patients With Type II Diabetes". The primary objective of this trial is to measure changes in hepatic lipid content using three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
What is the current status of trial NCT02365233?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2013-05-01. Estimated completion is 2016-12-31.
What interventions are being tested in trial NCT02365233?
The interventions under investigation include: Pioglitazone (DRUG), DPP4 inhibitor (DRUG), Lantus insulin (DRUG).
Who is sponsoring clinical trial NCT02365233?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.